CDK4 and medulloblastoma: Jude Children’s research hospital (NCT03434262, SJDAWN) compares multiple combinations of molecularly driven therapies in pediatric patients with medulloblastoma, and it includes an arm that evaluates the combination of sonidegib with ribociclib, a CDK4/6 inhibitor, in refractory/recurrent cases of SHH-activated medulloblastoma.